Nature Medicine

Nature Medicine
Title	Nature Medicine
Discipline	Medicine
Abbreviation	Nat. Med.
Publisher	Springer Nature
Country	United Kingdom
History	1995–present
Frequency	Monthly
Impact	64.8 (2023)

Nature Medicine is a monthly peer-reviewed medical journal published by Springer Nature focusing on clinical research, translational science, and biomedical advances. It serves as a venue for original research, reviews, and commentary that aim to bridge laboratory discoveries and clinical application, attracting submissions from investigators affiliated with institutions such as Harvard Medical School, Johns Hopkins University, Massachusetts Institute of Technology, University of Oxford, and Stanford University. The journal engages with topics spanning molecular biology, clinical trials, public health crises like COVID-19 pandemic, and biomedical technologies developed at places like Broad Institute and Salk Institute.

History

The journal was established in 1995 during a period of rapid expansion in biomedical publishing alongside titles such as The New England Journal of Medicine and The Lancet. Its founding aligned with growth at the parent publisher, Macmillan Publishers (later part of Springer Nature), and with contemporaneous developments at research centers including National Institutes of Health, Wellcome Trust, and Howard Hughes Medical Institute. Throughout the 2000s and 2010s the journal published landmark reports connected to initiatives like the Human Genome Project follow-ups and trials influenced by standards from agencies such as the U.S. Food and Drug Administration and European Medicines Agency.

Scope and Editorial Policy

The scope emphasizes translational and clinical research involving investigators from institutions like Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, and Dana–Farber Cancer Institute. Editorial policy requires disclosure of conflicts of interest and adherence to guidelines from organizations such as the International Committee of Medical Journal Editors, Committee on Publication Ethics, and trial registration norms exemplified by ClinicalTrials.gov entries. The journal enforces reporting standards informed by frameworks such as CONSORT used by randomized trials occurring at sites including Kaiser Permanente and trials overseen by entities like World Health Organization.

Publication and Impact

Publication produces original research articles, reviews, perspectives, and correspondence drawing authors from universities including Yale University, University of California, San Francisco, Imperial College London, and Peking University. The journal’s citation metrics place it among high-impact medical journals alongside Cell, Nature, and Science. Its editorial decisions influence clinical guidelines formulated by bodies such as American Heart Association, European Society of Cardiology, and policy deliberations at agencies including Centers for Disease Control and Prevention and National Health Service panels. The journal has featured work underpinning therapies developed by companies like Genentech, Moderna, and Pfizer.

Notable Articles and Contributions

Notable contributions include early translational reports that informed strategies during the Ebola virus epidemic and the COVID-19 pandemic, studies linked to oncology breakthroughs such as immune checkpoint blockade pioneered by researchers associated with University of Chicago and University of Pennsylvania, and gene-editing translational studies related to CRISPR research originating from teams at University of California, Berkeley and Broad Institute. Articles have intersected with major collaborative projects like the Cancer Genome Atlas and innovations developed at Grail, Inc. and Illumina. Reviews and commentaries influenced debates around public health interventions promoted by organizations such as Bill & Melinda Gates Foundation and Global Fund to Fight AIDS, Tuberculosis and Malaria.

Editorial Board and Peer Review Process

The editorial board has included senior editors and advisory members drawn from institutions including Columbia University, University of Cambridge, Karolinska Institutet, and University of Tokyo. Peer review follows a model employing external referees frequently affiliated with research centers like Fred Hutchinson Cancer Research Center, Scripps Research, and Ragon Institute; statistical and methodological assessment often references standards from CONSORT and regulatory expectations from European Medicines Agency. Editorial oversight coordinates with professional societies such as American Society of Clinical Oncology and Infectious Diseases Society of America when commissioning reviews and guidelines.

Controversies and Retractions

As with other leading biomedical journals, the title has faced controversies including debates over reproducibility highlighted by investigations akin to those impacting journals like Science and The Lancet, manuscript disputes involving competing groups from institutions such as University of Pennsylvania and Harvard Medical School, and occasional retractions following institutional inquiries at universities including University of Toronto and Peking University. High-profile editorial decisions have drawn commentary from stakeholders including National Institutes of Health program officers and ethics bodies such as Committee on Publication Ethics.

Category:Medical journals Category:Springer Nature journals